Paolillo (Merck), in Neurology Next to Patients, From Multiple Sclerosis to Rare Diseases For
This story is only covered by news sources that have yet to be evaluated by the independent media monitoring agencies we use to assess the quality and reliability of news outlets on our platform. Learn more here.4 Articles
4 Articles
For more than 25 years we have been dealing with multiple sclerosis, a pathology that in this period has seen the arrival of many drugs capable of offering new hopes and possibilities to patients. "We are entering the world of rare neurological diseases and, in particular, we are dealing with neurofibromatosis type 1 with plexiform neurofibromas. Merck has a new therapeutic option that can offer relief, improve symptoms and, therefore, the quali…
For more than 25 years we have been dealing with multiple sclerosis, a pathology that in this period has seen the arrival of many drugs capable of offering new hopes and possibilities to patients.We are entering the world of rare neurological diseases and, in particular, we are dealing with neurofibromatosis type 1 with plexiform neurofibromas. Merck presents a new...Continue readingThe article Paolillo (Merck), in neurology next to patients, fr…
Rec News | Lontani dal mainstream
notizie.itFor more than 25 years we have been dealing with multiple sclerosis, a pathology that in this period has seen the arrival of many drugs capable of offering new hopes and possibilities to patients.We are entering the world of rare neurological diseases and, in particular, we are dealing with neurofibromatosis type 1 with plexiform neurofibromas. Merck presents a new [...] L'articolo Paolillo (Merck), "In neurology next to patients, from multiple …
Coverage Details
Bias Distribution
- There is no tracked Bias information for the sources covering this story.
Factuality
To view factuality data please Upgrade to Premium
